论文部分内容阅读
目的探讨肺癌中p53和nm23与GST Pi、ToPoⅡ、P gp表达的相关性及预后意义。方法用免疫组化法对76例肺癌进行p53、nm23、GST Pi、ToPoⅡ和P gp检测分析,并随访。结果76例肺癌中p53、nm23、GST Pi、ToPoⅡ、P gp的阳性表达率依次为76.3%、17.1%、51.3%、25.0%和15.8%。p53和nm23表达与GST Pi、ToPoⅡ、P gp三种耐药基因表达无关(P>0.05),与淋巴结转移相关(P<0.01)。三种耐药基因的阳性表达与肺癌的组织学类型相关(P<0.05),与淋巴结转移及临床分期相关(P≤0.01),与性别、年龄无关(P>0.05)。结论部分肺癌患者体内存在多药耐药基因(MDR1)或对GST Pi、ToPoⅡ、P gp介导的抗癌药物已产生耐药。p53及nm23在肺癌中的表达与多药耐药无关;与淋巴结转移呈负相关,对判断肺癌的预后有重要意义。肺癌中多药耐药基因的表达与组织学类型、淋巴结转移、临床分期相关。
Objective To investigate the correlation and prognostic significance of p53 and nm23 expression with GST Pi, ToPoⅡ and P gp expression in lung cancer. Methods The expressions of p53, nm23, GST Pi, ToPoⅡ and P gp in 76 cases of lung cancer were detected by immunohistochemistry and followed up. Results The positive rates of p53, nm23, GST Pi, ToPoⅡ and P gp in 76 cases of lung cancer were 76.3%, 17.1%, 51.3%, 25.0% and 15.8%, respectively. The expressions of p53 and nm23 were not related to the expression of GST Pi, ToPoⅡ and P gp (P> 0.05), but correlated with lymph node metastasis (P <0.01). The positive expression of the three resistance genes was correlated with histological types of lung cancer (P <0.05), and lymph node metastasis and clinical stage (P≤0.01), but not with sex and age (P> 0.05). Conclusions Some patients with lung cancer have multidrug resistance gene (MDR1) in vivo or are resistant to GST Pi, ToPoⅡ and P gp-mediated anticancer drugs. The expression of p53 and nm23 in lung cancer has nothing to do with multidrug resistance, and is negatively correlated with lymph node metastasis, which is of great significance in judging the prognosis of lung cancer. The expression of multidrug resistance gene in lung cancer is related to histological type, lymph node metastasis and clinical stage.